Latest news and insights on the pharmaceutical industry | Indian Pharma Post | Page 185

Results For "IND"

6841 News Found

FDA approves Zydus’ Deflazacort oral suspension, 22.75 mg/mL
Drug Approval | October 07, 2025

FDA approves Zydus’ Deflazacort oral suspension, 22.75 mg/mL

Deflazacort oral suspension is indicated for treating Duchenne Muscular Dystrophy in patients 5 years of age and older


Alembic and Amlan launch feed additive solutions for poultry
News | October 07, 2025

Alembic and Amlan launch feed additive solutions for poultry

These products strengthen poultry immunity, improve productivity, and support sustainable farming practices~


Briefs: Shilpa Medicare and Medico Remedies
News | October 07, 2025

Briefs: Shilpa Medicare and Medico Remedies

Medico Remedies receives order worth US$ 1,781,000


Zydus receives approval from Health Canada for Liothyronine tablets 5 mcg and 25 mcg
Drug Approval | October 07, 2025

Zydus receives approval from Health Canada for Liothyronine tablets 5 mcg and 25 mcg

Liothyronine tablets will be manufactured at Zydus' plant in Ahmedabad SEZ


Lonza expands cell and gene therapy portfolio
Biotech | October 07, 2025

Lonza expands cell and gene therapy portfolio

Lonza boosts TheraPEAK line with new Cytokines and AAV Medium for next-gen therapies


Health Secretary Srivastava chairs meeting with states/UTs on quality and rational use of cough syrups
Policy | October 06, 2025

Health Secretary Srivastava chairs meeting with states/UTs on quality and rational use of cough syrups

States exhorted to ensure rational use of cough syrups, particularly among children, as most coughs are self-limiting and do not require pharmacological treatment


Evofem's SOLOSEC submitted for regulatory approval in the UAE
News | October 06, 2025

Evofem's SOLOSEC submitted for regulatory approval in the UAE

Marks first international filing for Evofem’s single-dose oral treatment


BMS’s anti-MTBR-Tau granted fast track designation by FDA for Alzheimer’s disease
Drug Approval | October 05, 2025

BMS’s anti-MTBR-Tau granted fast track designation by FDA for Alzheimer’s disease

Anti-microtubule binding region-tau antibody being investigated as a potential disease-modifying therapy to slow or delay progression of disease